Does a controlled-substance agreement actually protect you legally?

It documents informed consent and shows a board or carrier that your prescribing follows a written, consistently applied standard. The protection comes from enforcing it the same way for every patient; an agreement you waive for likable patients and enforce against difficult ones can be used against you. Have your attorney review the final wording.

Should every patient sign it, or only patients prescribed scheduled medications?

Common practice is to have it signed by any patient at the visit where a controlled medication is first prescribed, and to skip it for everyone else. Some practices put it in the standard intake packet instead so it is never forgotten. Either works; signing only when relevant keeps the intake stack shorter for the majority who never need it.

What if an established patient refuses to sign?

Refusal is clinical information, and it usually predicts the conflicts the agreement exists to prevent. You can continue treating the patient while declining to prescribe scheduled medication without a signed agreement. Present it as the standing condition attached to these prescriptions for every patient in the practice.

A Controlled-Substance Agreement Template for Psychiatry

A controlled-substance agreement is a one-to-two page document that every patient on a stimulant, benzodiazepine, or other scheduled medication signs before the first prescription. It fixes the rules in advance: how often you meet, how refills work, what happens when a script is lost, which pharmacy fills it, what monitoring you consent to, and what ends prescribing. Once it exists, every edge case becomes "the policy says," instead of a fresh negotiation you conduct alone at 4:45 p.m. on a Friday. The template is below, with the reasoning behind each clause so you can adjust the numbers instead of copying them blind.

This is practice-operations guidance. It is not legal or medical advice. Have your attorney and malpractice carrier review your final agreement, and make every prescribing decision on your own clinical judgment. The law underneath telehealth prescribing (Ryan Haight, the DEA flexibilities that currently run through December 31, 2026) is covered in our telehealth controlled-substances guide; this page covers the policy layer your practice controls.

The agreement template

Copy it, replace the bracketed values, have your attorney adapt it to your state, and add it to the intake packet in your EHR as a required signature before the first controlled prescription.

CONTROLLED SUBSTANCE TREATMENT AGREEMENT

This agreement applies to any controlled (scheduled) medication prescribed
by [Practice Name], including stimulants and benzodiazepines.

Treatment and evaluation
1. Controlled medications are prescribed as a treatment trial. Continuing
   one depends on benefit, safety, and adherence to this agreement, as
   assessed at follow-up visits.
2. If I transfer in on an existing regimen, [Provider Name] will review my
   records, prescription history, and clinical picture before deciding what
   to prescribe. Continuation of a prior regimen is never guaranteed.

Visits and refills
3. I will attend follow-up visits at the frequency my prescriber sets:
   typically monthly while a dose is new or changing, and every [2-3]
   months once stable. Renewals are issued at or after these visits.
4. I will request refills at least [3] business days before I run out.
   Refill requests are handled during business hours only.
5. Early refills are provided only for a documented reason. If I will be
   away when a refill is due, I will raise it at a visit in advance;
   prescriptions may be issued with an earliest-fill date.
6. I will report lost, damaged, or stolen medication to [Practice Name]
   and my pharmacy immediately. A police report may be required for stolen
   medication. At most one replacement will be considered in any 12-month
   period; a second event may end controlled-substance prescribing.

Safety and monitoring
7. I will fill all controlled prescriptions at one pharmacy: ____________.
   I will tell the practice before changing pharmacies. If a documented
   shortage means my pharmacy cannot fill a prescription, the practice
   will work with me to send it elsewhere.
8. I will receive controlled medications only from [Provider Name] and
   will disclose any prescription from another clinician. I understand the
   practice checks the state prescription monitoring program (PDMP) at
   intake and on an ongoing basis.
9. I agree to random urine or oral drug screens and medication counts when
   requested. Unexpected results are discussed first; unexplained results
   or refusal to test may end controlled-substance prescribing.
10. I will take the medication only as prescribed, will never change my
    dose without approval, and will never share, sell, or give it to
    anyone. I will store it securely.

Ending controlled prescribing
11. Prescribing may stop, after discussion, for: undisclosed controlled
    prescriptions from other providers, altered or forged prescriptions,
    unexplained screening results, repeated lost or stolen reports,
    repeated missed appointments, or threatening behavior toward staff.
12. Stopping a controlled medication does not automatically end my care.
    Where stopping abruptly is unsafe, [Provider Name] will provide a
    taper or a referral consistent with good medical practice.

Patient signature: _______________________  Date: ___________
Prescriber signature: ____________________  Date: ___________

The structure follows the same skeleton as the public sample agreements worth reading before you finalize yours: the Kentucky Board of Medical Licensure's sample controlled-substance agreement and the Kaiser Permanente ADHD clinic stimulant agreement.

1. Decide the new-patient rule before the first consult call

A screening call promises an evaluation, never a prescription. That one rule saves the most grief. Callers who open with "I just need my Adderall refilled" are asking you to commit to a regimen you have never assessed. The answer that works, said the same way every time: "My process is records, a full evaluation, and then a prescription decision. I never continue or start a controlled medication before that evaluation is complete." Patients seeking a prescriber rather than a prescription accept this readily; the rest filter themselves out before they cost you an intake slot. The broader mechanics of that call are in how to screen new patients.

For a stimulant start, common intake practice includes a full psychiatric history, prior records, a PDMP check, baseline vitals, and cardiac screening where history indicates it. Write your own list down once and apply it every time.

2. Write the transfer rule for patients arriving on high doses

The hardest intake is a transfer already on a regimen at or above labeled maximums who wants it continued untouched. Prescribers handle this in two defensible ways. Some put an explicit dose ceiling in the written policy and decline patients who will only accept continuation above it. Others take these patients, since high doses usually accumulated for a reason, and use the evaluation to find what drove the escalation, often untreated anxiety, a sleep disorder, or trauma. Either path works; choosing it in advance, in writing, is what keeps the decision clinical instead of a doorstep negotiation.

"On a screening call I promise an evaluation and nothing else," says Juan Rodriguez, MD, the psychiatrist who reviewed this guide. "Every transfer hears the same sentence: once I have your records and we finish a full evaluation, we decide together what I can safely prescribe."

3. Set refill mechanics: notice, early requests, lost scripts

Schedule II medications cannot be refilled under federal law; every fill needs a new prescription. For stable patients, 21 CFR 1306.12(b) lets you issue multiple prescriptions at one visit covering up to a 90-day total supply, each after the first marked with an earliest date it may be filled. Some states restrict this, so confirm yours allows it first. Schedule III and IV medications may be refilled up to five times in six months.

The clauses community practice has converged on, and that both public sample agreements above contain in some form:

Clause	Common-practice version
Refill notice	2 to 3 business days before running out
After-hours refills	None on nights, weekends, or holidays
Early refills	Documented reason only; travel handled with earliest-fill dates
Lost or stolen	Immediate report to practice and pharmacy; police report for theft
Replacement limit	One per 12 months; the Kentucky sample allows discharge after two events in a year

The replacement limit is the clause most often missing from homegrown policies, and it is the one that ends the "my bag was stolen again" cycle without an argument.

4. Fix the monitoring cadence: PDMP, drug screens, one pharmacy

Every state now runs a prescription drug monitoring program, and most mandate checking it before prescribing at least some scheduled medications; when and how often varies by state. Common practice for a psychiatric panel: check at intake, then before each renewal cycle for stimulants and benzodiazepines, or at whatever interval your state mandates if stricter.

Random drug screens earn their place in the agreement even if you rarely order them. Stable patients commonly see a baseline screen at the start of controlled prescribing and then a random screen roughly once or twice a year, with more frequent testing when something changes. The clause matters more than the cadence: what triggers action is an unexplained result or a refusal, and both need to be named in writing before they happen.

The one-pharmacy clause appears in both public samples: it keeps the PDMP picture readable and makes doctor-shopping visible. It needs the shortage exception built into clause 7, covered next.

5. Tie follow-up frequency to renewals

The common-practice range is monthly visits while a dose is new or changing, then every 2 to 3 months once stable, with 90 days the usual outer limit for stimulants. Benzodiazepines usually run tighter; many prescribers want a visit before each renewal. Present your numbers as the standing schedule attached to the medication class, and the pushback largely disappears.

Enforcement comes free once renewals are tied to visits: a patient who no-shows has a scheduling problem to solve before the next renewal, and your no-show policy handles the rest. The policy also absorbs the emotional labor: without one, every stretch request becomes a personal judgment call, and solo prescribers swing between too lenient and too rigid until the swings burn them out.

6. Add a shortage clause so supply problems don't break the policy

The FDA posted the Adderall shortage on October 12, 2022, and stimulant supply has been intermittently unreliable ever since. Without a shortage exception, your own one-pharmacy clause turns a stockout into a violation, so clause 7 builds the exception in: a documented shortage lets the prescription move.

What prescribers report working during a stockout: smaller independent and grocery-store pharmacies often have stock when the big chains are dry, and a direct prescriber-to-pharmacist call surfaces inventory that patients are told cannot be discussed. Empathy works better than pressure; the pharmacist is having the same bad month you are. Switching a stranded patient to an alternative agent is a clinical call for the chart, outside this document's scope.

7. Name what ends prescribing, and what happens next

Clause 11 lists the triggers; your job is deciding the response ladder before you need it. Most violations earn one documented conversation and tightened terms: shorter fills, more frequent visits, a screen. A few are one-strike by near-universal convention, altered or forged prescriptions and evidence of diversion chief among them. Apply the ladder identically to every patient; selective enforcement is what turns a protective document into a liability.

Keep two endings distinct. Ending controlled prescribing changes the treatment plan while the patient stays in your care; where abrupt discontinuation is unsafe, especially with benzodiazepines, clause 12's taper-or-refer language is a clinical obligation. Ending the relationship itself carries notice periods and abandonment rules of its own; when a violation warrants it, follow the full sequence in how to discharge a patient.

The checklist

Signed before the first controlled prescription; stored with the intake packet in your EHR
Screening-call rule: promise the evaluation, never the regimen
Transfer rule written down: a dose ceiling or a close-monitoring path, chosen in advance
Refill notice in business days; no after-hours or weekend refills
Lost or stolen: immediate report, police report for theft, one replacement per 12 months
PDMP at intake and per your state's mandate or stricter; random screens consented in writing
One pharmacy, with a documented-shortage exception
Follow-ups monthly while changing, every 2 to 3 months stable; renewals tied to visits
Termination triggers listed, with taper language for unsafe stops